Annals of Surgical Treatment and Research

  • 제95권6호
  • /
  • Pages.303-311
  • /
  • 2018
  • /
  • 2288-6575(pISSN)
  • /
  • 2288-6796(eISSN)
대한외과학회 (The Korean Surgical Society)
권호 표지
DOI QR코드

DOI QR Code

Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas

  • Ha, Su-Min (Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Hwang, Shin (Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Jin Young (CbsBioscience, Inc.) ;
  • Lee, Young-Joo (Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Ki-Hun (Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Song, Gi-Won (Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jung, Dong-Hwan (Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yu, Yun-Suk (CbsBioscience, Inc.) ;
  • Kim, Jinpyo (CbsBioscience, Inc.) ;
  • Lee, Kyoung-Jin (Department of Fusion Medicine, Asan Medical Center) ;
  • Tak, Eunyoung (Department of Fusion Medicine, Asan Medical Center) ;
  • Park, Yo-Han (Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine) ;
  • Lee, Sung-Gyu (Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2018.04.19
  • 심사 : 2018.07.12
  • 발행 : 2018.12.01
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: OncoHepa test is a multigene expression profile test developed for assessment of hepatocellular carcinoma (HCC) prognosis. Multiplication of ${\alpha}$-FP, des-${\gamma}$-carboxy prothrombin (DCP) and tumor volume (TV) gives the ${\alpha}$-FP-DCP-volume (ADV) score, which is also developed for assessment of HCC prognosis. Methods: The predictive powers of OncoHepa test and ADV score were validated in 35 patients who underwent curative hepatic resection for naïve solitary HCCs ${\leq}5cm$. Results: Median tumor diameter was 3.0 cm. Tumor recurrence and patient survival rates were 28.6% and 100% at 1 year, 48.6% and 82.9% at 3 years, and 54.3% and 71.4% at 5 years, respectively. The site of first tumor recurrence was the remnant liver in 18, lung in 1, and the peritoneum in 1. All patients with HCC recurrence received locoregional treatment. OncoHepa test showed marginal prognostic significance for tumor recurrence and patient survival. ADV score at 4log also showed marginal prognostic difference with respect to tumor recurrence and patient survival. Combination of these 2 tests resulted in greater prognostic significance for both tumor recurrence (P = 0.046) and patient survival (P = 0.048). Conclusion: Both OncoHepa test and ADV score have considerably strong prognostic power, thus individual and combined findings of OncoHepa test and ADV score will be helpful to guide postresection surveillance in patients with solitary HCCs ${\leq}5cm$.

키워드

과제정보

연구 과제 주관 기관 : National Research Foundation of Korea (NRF)

참고문헌

  1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
  2. Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, et al. The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J Gastrointest Surg 2015;19:1281-90. https://doi.org/10.1007/s11605-015-2849-5
  3. Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, Moon DB, et al. Multiplication of tumor volume by two tumor markers is a post-resection prognostic predictor for solitary hepatocellular carcinoma. J Gastrointest Surg 2016;20:1807-20. https://doi.org/10.1007/s11605-016-3187-y
  4. Shindoh J, Andreou A, Aloia TA, Zimmitti G, Lauwers GY, Laurent A, et al. Microvascular invasion does not predict longterm survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol 2013;20:1223-9. https://doi.org/10.1245/s10434-012-2739-y
  5. Shindoh J, Hasegawa K, Inoue Y, Ishizawa T, Nagata R, Aoki T, et al. Risk factors of post-operative recurrence and adequate surgical approach to improve long-term outcomes of hepatocellular carcinoma. HPB (Oxford) 2013;15:31-9. https://doi.org/10.1111/j.1477-2574.2012.00552.x
  6. Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, et al. Resection of hepatocellular cancer ${\leq}$2 cm: results from two Western centers. Hepatology 2013;57:1426-35. https://doi.org/10.1002/hep.25832
  7. Kim J, Hong SJ, Park JY, Park JH, Yu YS, Park SY, et al. Epithelial-mesenchymal transition gene signature to predict clinical outcome of hepatocellular carcinoma. Cancer Sci 2010;101:1521-8. https://doi.org/10.1111/j.1349-7006.2010.01536.x
  8. Hwang S, Ha TY, Song GW, Jung DH, Ahn CS, Moon DB, et al. Quantified Risk assessment for major hepatectomy via the indocyanine green clearance rate and liver volumetry combined with standard liver volume. J Gastrointest Surg 2015;19:1305-14. https://doi.org/10.1007/s11605-015-2846-8
  9. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. https://doi.org/10.3350/cmh.2016.22.1.18
  10. Jung DH, Hwang S, Lee YJ, Kim KH, Song GW, Ahn CS, et al. Small hepatocellular carcinoma with low tumor marker expression benefits more from anatomical resection than tumors with aggressive biology. Ann Surg 2017 Aug 23 [Epub]. https://doi.org/10.1097/SLA.0000000000002486.
  11. Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 2009;28:20. https://doi.org/10.1186/1756-9966-28-20
  12. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of realtime quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
  13. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086-92. https://doi.org/10.1002/lt.20472
  14. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009;1796:75-90.
  15. Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 2009;50:1464-74. https://doi.org/10.1002/hep.23221
  16. Kowanetz M, Valcourt U, Bergstrom R, Heldin CH, Moustakas A. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol 2004;24:4241-54. https://doi.org/10.1128/MCB.24.10.4241-4254.2004
  17. Tsunedomi R, Iizuka N, Tamesa T, Sakamoto K, Hamaguchi T, Somura H, et al. Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor. Clin Cancer Res 2008;14:1025-31. https://doi.org/10.1158/1078-0432.CCR-07-1116
  18. Damdinsuren B, Nagano H, Kondo M, Yamamoto H, Hiraoka N, Yamamoto T, et al. Expression of Id proteins in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Int J Oncol 2005;26:319-27.
  19. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-75. https://doi.org/10.1038/nrc1949
  20. Przybylo JA, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail's pace. Int J Biochem Cell Biol 2007;39:1082-8. https://doi.org/10.1016/j.biocel.2007.03.002
  21. Sakamoto Y, Mafune K, Mori M, Shiraishi T, Imamura H, Mori M, et al. Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. Int J Oncol 2000;17:237-43.
  22. Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002;8:385-92. https://doi.org/10.3748/wjg.v8.i3.385
  23. Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 1996;24:1058-62. https://doi.org/10.1002/hep.510240513
  24. Chen ZB, Shen SQ, Ding YM, Wang WX, Tao JP, Liang LJ, et al. The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus. Med Oncol 2009;26:365-71. https://doi.org/10.1007/s12032-008-9130-7
  25. Perez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F, Nieto MA, et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelialmesenchymal transitions. J Biol Chem 2001;276:27424-31. https://doi.org/10.1074/jbc.M100827200
  26. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39. https://doi.org/10.1016/j.cell.2004.06.006
  27. Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with earlystage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 2017;35:2838-47. https://doi.org/10.1200/JCO.2017.74.0472
  28. Delahaye LJ, Drukker CA, Dreezen C, Witteveen A, Chan B, Snel M, et al. A breast cancer gene signature for indolent disease. Breast Cancer Res Treat 2017;164:461-6. https://doi.org/10.1007/s10549-017-4262-0
  29. Vaira V, Roncalli M, Carnaghi C, Faversani A, Maggioni M, Augello C, et al. MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. Liver Int 2015;35:1077-86. https://doi.org/10.1111/liv.12636
  30. Chen R, Guan Q, Cheng J, He J, Liu H, Cai H, et al. Robust transcriptional tumor signatures applicable to both formalinfixed paraffin-embedded and fresh-frozen samples. Oncotarget 2017;8:6652-62.

피인용 문헌

  1. Alpha-fetoprotein is correlated with intrahepatic recurrence of hepatocellular carcinoma after a hepatectomy vol.98, pp.4, 2020, https://doi.org/10.4174/astr.2020.98.4.168
  2. Salvage living donor liver transplantation for hepatocellular carcinoma recurrence after hepatectomy: Quantitative prediction using ADV score vol.28, pp.11, 2021, https://doi.org/10.1002/jhbp.863